Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2206
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Effects of Herceptin on Circulating Tumor Cells in HER2 Positive Early Breast Cancer

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2015English

Therapy Landscape in Patients With Metastatic HER2-Positive Breast Cancer: Data From the PRAEGNANT Real-World Breast Cancer Registry

Cancers
Cancer ResearchOncology
2018English

Adjuvant Treatment of HER2-positive Breast Cancer: Winning Efforts Continue to Improve HER2-positive Patient Outcome Long-Term

Breast Cancer Research
Cancer ResearchOncology
2012English

New Developments in the Treatment of HER2-positive Breast Cancer

Breast Cancer: Targets and Therapy
Oncology
2012English

Octreotide LAR and Tamoxifen Versus Tamoxifen in Phase III Randomize Early Breast Cancer Trials: NCIC CTG MA.14 and NSABP B-29

Breast Cancer Research and Treatment
Cancer ResearchOncology
2015English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Current Approaches and Future Directions in the Treatment of HER2-positive Breast Cancer

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2013English

Brain Metastases in Asian HER2-positive Breast Cancer Patients: Anti-Her2 Treatments and Their Impact on Survival

British Journal of Cancer
Cancer ResearchOncology
2012English

Comparison of the Prognostic and Predictive Utilities of the 21-Gene Recurrence Score Assay and Adjuvant! For Women With Node-Negative, ER-positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

Breast Cancer Research and Treatment
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy